Table 1 Baseline data of clinical patients. 30 specimens were used in the research. All specimens were divided into two groups dependent of the expression of SLC3A2. In addition, the specimens were also classification of gender, age, pathological stage and grade
From: SLC3A2 inhibits ferroptosis in laryngeal carcinoma via mTOR pathway
| Â | Low_exp | High_exp | P-value |
|---|---|---|---|
Total | 19 | 11 | / |
Gender | Â | Chi square test | |
 male | 10 | 5 | p > 0.05 |
 female | 9 | 6 | |
Age |  | p > 0.05 | |
  < 65 | 6 | 4 | |
  > =65 | 13 | 7 | |
Stage |  | P = 0.030 | |
 I | 8 | 1 | |
 II | 6 | 1 | |
 III | 3 | 4 | |
 IV | 2 | 5 | |
Grade |  | P = 0.049 | |
 1 | 7 | 1 | |
 2 | 8 | 2 | |
 3 | 2 | 4 | |
 4 | 2 | 4 | |